Yusen Logistics strengthens presence in Mexico with new branch in Guadalajara
Yusen Logistics, a leading third-party logistics provider, is expanding its air freight forwarding network in Mexico with the addition of a branch in Guadalajara.
List view / Grid view
News
FDA approves IDE study for bone graft substitute, Cerament G
10 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Bonesupport’s Fortify study will evaluate the safety and efficacy of Cerament G as part of surgical repair of open diaphyseal tibial fractures. The trial will enrol up to 230 patients at up to 30 centres globally, with the aim of having at least 50% of the study data coming from…
Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug
9 August 2016 | By AstraZeneca
The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously...
MSD’s Hepatitis C drug given green light for EU market
9 August 2016 | By MSD
Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with…
Microbiological environmental monitoring features in two national conferences supported by Cherwell Laboratories
9 August 2016 | By Cherwell Laboratories
Cherwell to offer expert insight in environmental monitoring and process validation to both NHS and industrial pharmaceutical manufacturers...
NHS Scotland approves Novo Nordisk’s diabetes drug
9 August 2016 | By Novo Nordisk
The drug was approved using evidence from three phase III studies in adults with type 1 diabetes mellitus and five phase III studies in adults with type 2 diabetes mellitus. The researchers discovered that insulin degludec was non-inferior to other long-acting insulin analogues, assessed by the mean change in glycosylated…
Joint article on hydrogen peroxide efficacy published in letters in applied microbiology
8 August 2016 | By Wickham Laboratories
Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection by hydrogen peroxide...
Pfizer’s Vyndaqel a success for rare disease
8 August 2016 | By Pfizer
Treatement over varying periods of up to 5.5 years, showed that early stage treatment with Vyndaqel resulted in minimal neurological disease progression, and in preservation of body weight, which often declines as the disease progresses...
New England Biolabs® launches NEBNext Direct™ Technology with Cancer HotSpot Panel
8 August 2016 | By New England Biolabs, Inc.
Novel target enrichment technology, compatible with low input amounts from challenging sample types, uses a one-day workflow...
FDA approves Merck’s head and neck cancer drug
8 August 2016 | By Merck
Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon…
SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
EU approval in sight as Bellicum’s BPX-501 granted orphan drug designation
5 August 2016 | By Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, a clinical stage biopharmaceutical company, has been granted orphan drug designations for both its T-cell therapy product candidate BPX-501 for treatment in hematopoietic stem cell transplantation (HSCT), and for activator agent rimiducid...
Eczema wounds diseased by S. aureus contamination
5 August 2016 | By Erasmus MC University
A new study has revealed that 70% of eczema patients are colonised with Staphylococcus aureus bacteria (S. aureus, including MRSA) on their skin lesions...
NICE recommends secukinumab for people with ankylosing spondylitis
4 August 2016 | By National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back....
ReNeuron Group publishes stroke clinical data
4 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The PISCES I study was the first clinical trial of ReNeuron’s CTX cell therapy candidate for patients with motor disability as a consequence of ischaemic stroke. The data, collated over two years relates to the eleven stroke patients treated in the study...
